SRZN

Announcements

Nothing here yet

Daily updates

• Surrozen received FDA IND clearance for SZN-8141, enabling the Phase 1b/2a DUET trial in diabetic macular edema, with initial dosing expected in Q4 2026. The milestone also unlocked the second tranche of its March 2025 private placement, expected to provide nearly $95.1 million in gross proceeds to advance SZN-8141, SZN-8143, and operations.Oct 2, 2026

FDA designations

Nothing here yet

News

• Surrozen announces FDA clearance of the IND application for SZN-8141 to treat diabetic macular edemaOct 2, 2026
• Surrozen submitted an IND application for SZN-8141 to treat diabetic macular edemaSep 8, 2026
• Surrozen granted patent from U.S. Patent and Trademark Office for antibody-based molecules targeting key receptors in the Wnt pathway.May 14, 2025